1078P - Polymorphisms of GSTT1 and GSTM1 genes in diffuse large B cell lymphoma Egyptian patients

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Lymphomas
Pathology/Molecular Biology
Basic Scientific Principles
Presenter Hagar Alagizy
Authors H.A. Alagizy1, E. Essa2
  • 1Clinical Oncology Dept., Menofia University, 32514 - Shebin Elkom/EG
  • 2Clinical Pathology, menofia unevesity, shebin elkom/EG



Evidence, although not so extensive, did show that genetic variations in glutathione S-transferase (GST) might be associated with risk of developing lymphoma; overall and/or subtype. Genetic data on the contribution of GST genes in the prognosis of lymphomas is scarce even in occupationally exposed populations.


The study aimed to investigate the influence of polymorphisms in GSTM1 and GSTT1 genes on both the risk and prognosis of diffuse large B-cell lymphoma (DLBCL).

Subjects and methods

The study included 83 newly diagnosed DLBCL patients that were compared to 89 age and gender matched control subjects.Patient's stage, LDH, performance status, extranodal disease and age were assessed and international prognostic index (IPI) was plotted . Treatment outcome and follow up relapse/progression and death was done. .GSTM1 and GSTT1 genotyping was performed by a multiplex PCR protocol.


We found 2.35 fold increase in the risk of DLBCL associated with GSTT1-null genotype (OR = 2.35, 95% CI: 1.02 – 5.40, P = 0.04). Three times increased risk in individuals with the GSTM1/T1-double null genotype (OR3.06, 95% CI: 1.04 – 8.95, P = 0.03) compared with both GSTM1 and GSTT1 genes undeleted (wild genotype) was observed. Patients; overall and those with favorable IPI (<3), showing one GST-null genotype and those showing GSTM1/T1-double null genotype significantly had better progression free survival (PFS) and overall survival (OS) when compared with those showing both GST wild genes. Multivariate analysis showed that the presence of at least one GST-null genotype was associated with a 60% reduced risk of relapse/progression and 71 % reduced risk of death.


our results have shown a role for the GSTT1-null genotype and the GSTM1/T1-double null genotype as risk factors for DLBCL. The presence of at least one GST-null genotype tended to have a positive prognostic value for DLBCL patients independent from both the IPI score and the treatment outcome.


All authors have declared no conflicts of interest.